Lugano, Switzerland, 3 September 2024 – The ESMO Congress 2024 will take place from September 13-17 in Barcelona, bringing together participants from all over the world. Press representatives eager to grasp cutting-edge data and hearing expert perspectives on the latest research, as well as on the current and emerging hot topics in oncology, are invited to attend the event, which will be held both onsite and remotely.
The full congress program is available online to help press representatives browse regular and late-breaking abstract titles and navigate the 5 intense congress days, marked by a variety of scientific, educational sessions, special symposia and patient advocacy sessions.
The Congress programme this year will include, among others:
-
Studies that can change clinical practice: among them, new therapeutic combinations for the treatment of prostate cancer (LBA1), liver (LBA3) and cervical (709O) cancer, presented in Presidential Symposium 1 and bladder cancer (LB5) in Presidential Symposium 2.
-
Studies addressing cancers with high unmet needs: these include a Phase-3 trial with the potential to set a new standard of care in the treatment of anal cancer (LBA2) presented in Presidential Symposium 1. Encouraging early-stage trials also in glioblastoma and glioma (440O, 441O, 442O).
-
The long-term effects of immunotherapy in various disease settings: these include practice-changing Phase-3 trial in triple negative breast cancer (LBA4), presented in Presidential Symposium 2. Promising data also in the treatment of melanoma (LBA41, LBA43, LBA44).
-
Innovative approaches emerging and forward-looking discussions on new avenues in cancer research and care. These will be discussed in the Presidential Symposium 3, with topics ranging from the integration of AI applied to molecular diagnostics and treatment (LBA7, 1942O), through the application of systemic therapies to improve the quality of life of the patients (509O), from the need to investigate treatment resistance (LBA8) to pioneering solutions for poorly covered disease settings (604O).
-
Research poised to change the way patients are counseled: the under-explored area of safety of breastfeeding after breast cancer will be addressed in international studies (1814O, 1815O) that contribute to growing the body of evidence dismantling the barriers between motherhood and breast cancer.
-
Early-stage research in antibody-drug conjugates (ADCs): recent data on promising molecular targets across solid tumors (610O), including breast cancers (LBA18), salivary gland cancer (849MO) and advanced gynecological cancers (720MO, 721MO, 719MO).
-
The transformative impact of artificial intelligence on cancer care within the evolving field of precision medicine; the underlying factors contributing to the global epidemic of young age-onset cancer; the potential of clinical and preclinical science in understanding DNA repair mechanism will be addressed widely and deeply in the three keynote lectures.
Besides delving deeper into these and further congress highlights, the ESMO 2024 Opening Press Conference, Friday, 13 September (10:30-11:15 CEST), will be the occasion to address the evolution of therapeutic and technological landscapes, including the field of precision oncology. This rapidly changing environment stimulates the conversation on current and novel approaches to help the workforce keep pace with the change. The discussion will feature insights from:
-
Andrés Cervantes, INCLIVA – Biomedical Research Institute, Spain – ESMO President
-
Rebecca Dent, National Cancer Center Singapore, Republic of Singapore – ESMO 2024 Scientific Chair
-
Angela Lamarca, Fundacion Jimenez Diaz University Hospital, Spain - ESMO 2024 Press Officer
Press Conferences will be held during the subsequent Congress days (12:30-13:15 CEST) to engage press representatives in discussions concerning promising topics in oncology research, featuring some of the studies presented.
Further details about the press conferences will be published progressively here. All appointments for press will be held in the Press Conference Room (Hall CC3, Level 1), with a virtual option available. To attend the conferences, press representatives must be accredited for the Congress.
Press accreditation
ESMO welcomes press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities and the embargo schedule for the ESMO Congress 2024. To apply for press accreditation, please fill out the form available here.
Embargoed material availability
Only regular abstracts and LBAs covered in the ESMO press activities will be made available under embargo to accredited press representatives. They can access the embargoed resources through the ESMO Press Portal using their personal credentials. All other abstracts not included in ESMO press activities will be made available following the standard embargo schedule provided here.
Third Parties Media registration
Third Parties Media representatives and Filming Crews not eligible as press, must abide by the ESMO Policy on Media Activities Organised by Third Parties and can request a Third Parties Media badge through registration@esmo.org (Cc media@esmo.org).
Further information
ESMO Press Office
press@esmo.org
Notes to editors
Please make sure to use the official name of the meeting in your reports: ESMO 2024 and the official congress hashtag #ESMO24. Follow it to stay up to date and use it to take part in the conversation on X(Twitter), LinkedIn, Facebook, Instagram, YouTube.
About the European Society for Medical Oncology (ESMO)
Representing nearly 40,000 oncology professionals from 172 countries worldwide, ESMO is a reference for oncology education and information. Driven by a shared determination to secure the best possible outcomes for patients, ESMO is committed to standing by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE. www.esmo.org